https://www.selleckchem.com/pr....oducts/abraxane-nab-
4% vs 0.9%; P.0001) or liver decompensation (21.5% vs 1.3%; P.0001). Treatment with protease inhibitors was not associated with hepatic decompensation (P=.3). Only 82.6% of patients with decompensated cirrhosis completed DAA treatment (vs 92.8% in compensated cirrhotics; P.0001). Despite higher frequency of AE and treatment modifications, once completed, DAAs yield comparable results for patients with decompensated and compensated cirrhosis. High rate of serious adverse events in patients with advanced liver
Like
Comment
Share
